Issue #99

Deep value, proprietary platforms, and the regulatory dates you need to watch.

The biotech revolution isn’t being won by the most experimental lab results or the loudest press releases—it’s being decided quietly, in clinical trials and hospital wards where life-altering treatments for rare diseases are finally becoming a reality. As medicine moves from broad-spectrum treatments to precision therapies, two sectors matter more than anything else: the innovative chemistry platforms solving "unsolvable" infections, and the advanced delivery systems turning emergency room protocols into streamlined, life-saving procedures.

This is where the biotech conversation shifts from speculative science to essential healthcare infrastructure—and where the most resilient, high-potential winners are emerging.

👉 One company is leveraging a proprietary boron chemistry platform to tackle the global crisis of rare respiratory and neglected tropical diseases.

👉 The other is re-engineering critical care for neurological emergencies, transforming how hospitals treat life-threatening brain injuries.

👉 Both are currently being overlooked by the broader market, trading at significant discounts despite massive clinical catalysts arriving in the first half of 2026.

In this edition, we break down the molecular breakthroughs and the emergency-room innovations powering the next wave of rare disease cures—and why these two stocks sit at the foundation of the next decade of specialized medicine.

AN2 Therapeutics (NASDAQ: ANTX)

AN2 Therapeutics (NASDAQ: ANTX) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for rare, chronic, and serious infectious diseases. Leveraging its proprietary boron chemistry platform, the company aims to address significant unmet medical needs, particularly in respiratory and neglected tropical diseases where current treatments are either highly toxic or increasingly ineffective due to antibiotic resistance.

Business Model and Revenue Streams 📦

AN2 Therapeutics operates a typical high-stakes biotechnology business model, focusing on the Research and Development (R&D) of novel drugs rather than immediate commercial sales. The company’s primary engine is its boron-based chemistry platform, which allows for the creation of molecules with unique binding properties that traditional carbon-based drugs cannot achieve.

• R&D and Licensing Model: As a pre-revenue company, AN2 does not yet have an FDA-approved product on the market. Its "revenue" historically comes from strategic collaborations, such as its recent research agreement with GSK to advance inhibitors for Tuberculosis (TB). These partnerships provide non-dilutive funding through upfront payments and milestone-based rewards.
• Grant Funding: The company also aggressively pursues government support, evidenced by its significant contracts with the NIH and the Bill & Melinda Gates Foundation for global health initiatives like Chagas disease.

Macroeconomic Impact:

The current environment of stabilizing interest rates in 2026 has been a "breath of fresh air" for AN2. High rates previously penalized pre-revenue biotech firms by increasing the "cost of waiting" for clinical results. However, with the 2026 "biotech rebound," capital markets have thawed, making it easier for ANTX to maintain its cash runway through 2028. Despite this, the company remains sensitive to FDA policy shifts and inflationary pressures on clinical trial costs, which can impact the speed of their pipeline progression.

Recent Performance and Corporate Developments 📈

AN2 has recently pivoted its strategy following a volatile 2024 and 2025. While the company faced setbacks in its flagship Lung Disease program, it has successfully diversified its clinical portfolio to include oncology and rare blood disorders.

Q3 2025 Financial Highlights (Reported Nov 2025): 💰

• Revenue: $0.00. This is expected for a clinical-stage firm.
• Net Loss: $9.4 million. This was a notable improvement from the $12.7 million loss in Q3 2024, driven largely by lower R&D expenses as certain trials were streamlined.
• Cash Position: The company ended the period with $65.1 million, providing a safety net that management believes will sustain operations for the next two years.

Strategic Initiatives and Mergers: 🤝

On March 3, 2026, AN2 announced a major strategic expansion: advancing its lead candidate, Epetraborole, into a Phase 2 study for Polycythemia Vera (PV), a rare blood cancer. This move into oncology represents a significant broadening of their "pipeline-in-a-product" strategy. Additionally, in January 2026, the FDA cleared a 90-patient investigator-initiated trial for M. abscessus lung disease, keeping their respiratory program alive through low-cost, collaborative research. There have been no recent mergers, but the collaboration with GSK remains a key pillar of their infectious disease strategy.

Profitability and Fair Value 🎯

AN2 is not yet profitable and likely will not be until at least one of its candidates reaches the commercialization stage (estimated 2027–2028 at the earliest).

• Valuation: Currently, ANTX is trading at a significant discount to its book value. With a market cap hovering around $30 million and cash reserves of over $60 million, the market is essentially valuing the company at "less than the cash it has in the bank."
• Fair Value: Analysts suggest the stock is undervalued based on its Price-to-Book (P/B) ratio of approximately 0.5x, which is well below the industry average of 2.2x. This indicates that any positive clinical data could lead to a rapid upward "re-rating" of the stock price.

Analyst Estimates and Ratings 📊

• Consensus Rating: The stock has seen a surge in "Buy" interest over the last 30 days. Analysts view the current price level as a "deep value" entry point, especially with the new oncology trials starting in 2026.
• Price Target: The average 12-month price target currently sits near $1.05 to $2.67, though some aggressive estimates from late 2025 still point toward higher recovery levels if clinical milestones are met.

Investor-Focused Takeaway: Is ANTX Right for Your Portfolio?

AN2 Therapeutics is a "coiled spring" investment. It has the cash to survive for two years, and its current valuation is extremely low relative to its assets. It offers exposure to the rare disease and oncology sectors without the "bloated" valuations of larger peers.

What to Watch in the Near Term: 📈

• Phase 2 PV Enrollment: Watch for the start of the Polycythemia Vera trial in Q3 2026. Success here would pivot the company into a high-margin oncology player.
• Cash Burn: Monitor if the company maintains its $9M–$10M quarterly burn rate. Any spike without a corresponding clinical win could lead to shareholder dilution.
• Regulatory Catalysts: FDA feedback on their M. abscessus and Chagas programs will be the primary drivers of volatility throughout 2026.

Recommendation:

ANTX is a speculative "Buy" for investors with a high risk tolerance. The downside is partially protected by the company's cash-rich balance sheet, while the upside is tied to its transition from a pure "infectious disease" play to a broader "boron-platform" biotech.

Grace Therapeutics (NASDAQ: GRCE)

Grace Therapeutics (NASDAQ: GRCE) is a late-stage biopharmaceutical company specializing in the development of therapies for rare and orphan diseases. Its current primary focus is on neurological emergencies, specifically transforming how life-threatening brain injuries are treated in hospital settings. The company recently reverted to its original name, Grace Therapeutics (formerly Acasti Pharma), to align with its core scientific mission as it nears a critical regulatory milestone.

Business Model and Revenue Streams 📦

Grace Therapeutics utilizes a value-added drug delivery model. Rather than discovering entirely new chemical entities, the company re-engineers existing, proven medications using novel delivery technologies to improve their efficacy, safety, and ease of administration. This strategy significantly reduces the typical R&D timeline and risk profile associated with drug development.

• Lead Candidate (GTx-104): This is the heart of Grace’s value proposition. It is an intravenous (IV) formulation of nimodipine, a drug currently only available in oral form to treat aneurysmal Subarachnoid Hemorrhage (aSAH)—a rare, devastating type of brain bleed. By creating an IV version, Grace aims to solve the massive clinical hurdles of administering oral pills to unconscious or critically ill patients.
• Revenue Model: As a late-stage biotech, Grace is currently pre-revenue. Its future income is expected to flow from direct commercial sales in the U.S. hospital market (aSAH affects roughly 50,000 patients annually) and potential international licensing agreements.
• Macroeconomic Context: In 2026, Grace is operating in a favorable "risk-on" biotech market. Because the company is focusing on improving existing drugs (the 505(b)(2) regulatory pathway), it is less susceptible to the extreme binary risks of early-stage discovery. However, the company remains dependent on capital markets for funding until GTx-104 reaches the commercial stage.

Recent Performance and Corporate Developments 📈

The company is currently in a "pre-launch" phase, with all eyes on a looming FDA decision date.

Q3 Fiscal 2026 Financial Highlights (Ended Dec 31, 2025): 💰

• Net Loss: Grace reported a net loss of $2.3 million, a significant improvement from the $4.2 million loss in the same quarter of the previous year. This narrowing loss reflects a transition from expensive clinical trials to leaner pre-commercial planning.
• Earnings Beat: The company reported an EPS of -$0.14, beating analyst expectations by $0.14.
• Cash Position: As of early 2026, Grace holds approximately $18.7 million in cash. Management has stated this runway is sufficient to fund operations for at least the next 12 months, with an additional $15 million potentially available through warrant exercises.

Strategic Initiatives and Mergers: 🤝

There have been no recent mergers; however, the company’s corporate focus has narrowed entirely to the April 23, 2026, PDUFA date. This is the deadline by which the FDA must decide on the approval of GTx-104. In preparation, Grace has secured new patents covering IV dosing regimens that extend their intellectual property protection until 2043, creating a massive "moat" around their lead product.

Profitability and Fair Value 🎯

Grace is not yet profitable, but analysts are increasingly bullish as the "commercial window" opens.

• Profitability Path: Profitability is entirely contingent on the 2026 FDA approval and the subsequent launch of GTx-104. Because the hospital cost for aSAH patients averages $220,000, a more efficient IV treatment that reduces hospital stays or complications has a very clear path to insurance reimbursement and high margins.
• Fair Value: Currently, GRCE trades at roughly $4.00–$4.30. Many analysts consider this price to be a "distorted" floor. The company's book value is remarkably high compared to its market cap, and with the FDA decision just weeks away, the stock is currently priced as a "binary event" play rather than for its long-term market potential.

Analyst Estimates and Ratings 📊

• Consensus Rating: Grace currently holds a "Strong Buy" consensus. In the last 30 days, it has been highlighted as a top pick in the healthcare sector by firms such as H.C. Wainwright and Craig-Hallum.
• Price Target: The average 12-month price target is approximately $11.50, representing a massive potential upside of over 170% from current levels. Some high-end estimates reach as far as $12.00.

Investor-Focused Takeaway: Is GRCE Right for Your Portfolio?

Grace Therapeutics is a "catalyst-driven" stock. If GTx-104 is approved in April 2026, the company could transition from a $60 million market cap clinical-stage firm to a commercial-stage player with a protected monopoly on a critical hospital drug.

What to Watch in the Near Term: 📈

• April 23, 2026 (PDUFA Date): This is the single most important date for the company. FDA approval would likely trigger a massive re-valuation.
• Warrant Exercises: Watch for the company to "tap" its $15 million in warrant proceeds to fund the commercial sales team.
• Conference Presentations: Management is active on the 2026 conference circuit (including TD Cowen); listen for updates on their hospital distribution strategy.

Recommendation:

Grace (GRCE) is an ideal candidate for investors looking for near-term catalysts. While it carries the standard risks of FDA rejection, its late-stage status and massive analyst price-target gap make it one of the most talked-about "under the radar" biotech stocks of early 2026.

Final Take: The Molecular Platform and the Emergency Care Innovator

The biotech recovery of 2026 isn’t just about lab breakthroughs—it’s about clinical execution and addressing high-stakes, unmet medical needs. This requires two things: a chemistry platform that can reach previously "undruggable" targets and a delivery system that works in the most critical hospital environments.

That’s where AN2 Therapeutics (ANTX) and Grace Therapeutics (GRCE) stand apart.

🔬 AN2 Therapeutics (ANTX) — The Boron Chemistry Powerhouse

• ✔ Proprietary Platform: Leveraging unique boron-based molecules for rare infectious diseases and oncology.
• ✔ Deep Value: Trading significantly below cash-on-hand with a runway extending through 2028.
• ✔ Strategic Pivot: Expanding into rare blood cancers (Polycythemia Vera) to diversify beyond respiratory health.
• ➤ Best for: Deep-value investors looking for a "high-margin safety net" with massive upside potential from clinical re-rating.

🧠 Grace Therapeutics (GRCE) — The Critical Care Catalyst

• ✔ Near-Term Trigger: A defining FDA PDUFA date on April 23, 2026, for their lead candidate GTx-104.
• ✔ Market Monopoly: Secured patent protection through 2043 for the only IV formulation of a life-saving subarachnoid hemorrhage drug.
• ✔ Efficient Model: Using the 505(b)(2) pathway to lower R&D risk while targeting high-margin hospital settings.
• ➤ Best for: Catalyst-driven investors seeking a high-probability entry ahead of a major regulatory transition to commercial-stage status.

Investor Insight

🧩 Want a platform-play with deep-value protection and oncology upside? → ANTX

⚙️ Want near-term regulatory exposure with a clear path to market dominance? → GRCE

Bottom Line:

Rare disease cures don’t scale on hope—they scale on molecular precision and clinical accessibility.

AN2 Therapeutics owns the chemistry to fight rare pathogens, while Grace Therapeutics is perfecting the delivery of emergency brain-trauma care. As the market shifts toward specialized, late-stage biotech, ANTX and GRCE aren't just speculative bets—they are the foundational building blocks of the next generation of orphan drugs.

​
Happy Trading
​— Team Premium Stock Alerts